Exact FDA event identifier

Event 98258

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: October 20, 2025
Product types: Drug
Classifications: Class I
Statuses: Ongoing
Recalling firm wording: ANTHONY TRINH, 123Herbals LLC

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China

D-0388-2026

Recall number: D-0388-2026
Initiated: October 20, 2025
Classification: Class I
Status: Ongoing
Recalling firm: ANTHONY TRINH, 123Herbals LLC
Quantity: N/A

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Code information

All lots within expiry

Distribution pattern

USA nationwide